Journal of clinical immunology · 2008
Increased granulysin expression in peripheral blood cells of patients with primary biliary cirrhosis and its clinical implications.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Qian Cheng, Chen Sunxiao, Yao Dingkang, Wu Chuanyong, Jiang Tingwang, Ke Jinshan, Zhou Ye, Gu Mingli, Chen Bo, Deng Anmei, Zhong Renqian
Аннотация
INTRODUCTION: Granulysin is a cytotoxic molecule involved in cellular immune reactions.
MATERIALS AND METHODS: The levels of granulysin mRNA in the peripheral blood and serum granulysin of patients with primary biliary cirrhosis (PBC) were determined by quantitative polymerase chain reaction and enzyme-linked immunosorbent assay, respectively. The expression of granulysin mRNA and serum protein in PBC was increased compared to the controls.
RESULTS: The expression of granulysin mRNA or serum protein showed close associations, respectively, with natural killer cell population in PBC patients. Serum granulysin was down-regulated by steroid and ursodeoxycholic therapy for PBC according to the improvement of severity of PBC. In addition, the expression of serum granulysin were related to serum total bilirubin and Mayo Clinic risk score. The serum granulysin reflected the cellular immune status of patients with PBC, and the expression correlated with the severity of PBC.
CONCLUSION: Therefore, there is a clinical benefit to monitoring granulysin as a biomarker of the prognosis of patients with PBC.
MATERIALS AND METHODS: The levels of granulysin mRNA in the peripheral blood and serum granulysin of patients with primary biliary cirrhosis (PBC) were determined by quantitative polymerase chain reaction and enzyme-linked immunosorbent assay, respectively. The expression of granulysin mRNA and serum protein in PBC was increased compared to the controls.
RESULTS: The expression of granulysin mRNA or serum protein showed close associations, respectively, with natural killer cell population in PBC patients. Serum granulysin was down-regulated by steroid and ursodeoxycholic therapy for PBC according to the improvement of severity of PBC. In addition, the expression of serum granulysin were related to serum total bilirubin and Mayo Clinic risk score. The serum granulysin reflected the cellular immune status of patients with PBC, and the expression correlated with the severity of PBC.
CONCLUSION: Therefore, there is a clinical benefit to monitoring granulysin as a biomarker of the prognosis of patients with PBC.